Smith & Nephew
$40.819876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$40.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.23 (+0.57%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours
Why Robinhood?
You can buy or sell Smith & Nephew and other stocks, options, and ETFs commission-free!
About SNN
Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom. The listed name for SNN is Smith & Nephew plc.
CEO
Roland D. Diggelmann
Employees
17,637
Headquarters
Watford, Herefordshire
Founded
1937
Market Cap
18.46B
Price-Earnings Ratio
38.72
Dividend Yield
1.82
Average Volume
426.25K
High Today
$40.86
Low Today
$40.46
Open Price
$40.60
Volume
463.04K
52 Week High
$49.29
52 Week Low
$26.07
SNN News
ReutersFeb 18
UPDATE 3-Smith+Nephew sees further pandemic pain as annual profit slumps
* FY trading profit falls, misses average estimate
* Co encouraging employees to get vaccinated
* COVID-19 impact to continue into H1 2021
* Shares fall as m
Analyst Ratings
64%
of 14 ratings
Buy
64%
Hold
21%
Sell
14%
SNN Earnings
$0.00
$0.15
$0.31
$0.46
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 18, Pre-Market